<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656614</url>
  </required_header>
  <id_info>
    <org_study_id>Reversal Neuromuscular Block</org_study_id>
    <nct_id>NCT03656614</nct_id>
  </id_info>
  <brief_title>Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine</brief_title>
  <official_title>Dose Finding Study for Reversal of Vecuronium-induced Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to estimate the optimal dose of sugammadex and neostigmine reversal
      of a vecuronium-induced residual neuromuscular block at train-of-four ratio 0.3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sugammadex is a modified γ-cyclodextrin compound that reverses the neuromuscular blockade
      produced by steroidal nondepolarizing muscle relaxants such as rocuronium,vecuronium and
      pipecuronium by encapsulating them, making them unavailable to interact with the nicotinic
      acetylcholine receptors at the neuromuscular junction.However, residual neuromuscular blocks
      between reappearance of T4 and train-of-four ratio (TOFR)=0.5 are more frequent in clinical
      practice compared with profound or deep blocks and have not been investigated for sugammadex
      previously.

      Unlike neostigmine, sugammadex is efficacious in reversing profound (no responses to either
      train-of-four (TOF) or posttetanic count stimulation) or deep (posttetanic count of 1 or 2)
      neuromuscular block (NMB) in doses of 16 and 4 mg/kg, respectively. However, shallow
      neuromuscular blocks are more frequent in clinical practice compared with profound or deep
      blocks and have not been investigated for sugammadex previously.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">March 26, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 26, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>Time to TOF 0.9 after the administration of reversal agent</measure>
    <time_frame>the general anesthesia time 1 hour at least</time_frame>
    <description>The time to achieve TOF (Train of Four stimulation) ratio to 0.9 after sugammadex or neostigmine administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of reparalysis</measure>
    <time_frame>approximately 1 hour</time_frame>
    <description>Determining whether patients receiving reversal agent will have a train-to-four ratio &lt;0.8 during total recovery time (from TOF reach 0.9 first time to post-anaesthesia care unit (PACU) departure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse event</measure>
    <time_frame>the general anesthesia and recovery time 2 hours at least</time_frame>
    <description>Documenting whether patients will have some adverse events(such as hypoxia bradycardia nausea and vomiting) from anesthesia commence to PACU departure.</description>
  </secondary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>sugammadex 0.125</arm_group_label>
    <description>Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 0.25</arm_group_label>
    <description>Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 0.5</arm_group_label>
    <description>Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 1.0</arm_group_label>
    <description>Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 2.0</arm_group_label>
    <description>Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 5</arm_group_label>
    <description>Neostigmine group: neostigmine 5 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 10</arm_group_label>
    <description>Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 15</arm_group_label>
    <description>Neostigmine group: neostigmine 15 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 25</arm_group_label>
    <description>Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 50</arm_group_label>
    <description>Neostigmine group: neostigmine 50 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :
Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)</description>
    <arm_group_label>Sugammadex 0.25</arm_group_label>
    <arm_group_label>Sugammadex 0.5</arm_group_label>
    <arm_group_label>Sugammadex 1.0</arm_group_label>
    <arm_group_label>Sugammadex 2.0</arm_group_label>
    <arm_group_label>sugammadex 0.125</arm_group_label>
    <other_name>Bridion</other_name>
    <other_name>Org 25969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :
Neostigmine 5 µg/kg (Neostigmine 5) Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 15 µg/kg (Neostigmine 15) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 50 µg/kg (Neostigmine 50)
Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.</description>
    <arm_group_label>Neostigmine 10</arm_group_label>
    <arm_group_label>Neostigmine 15</arm_group_label>
    <arm_group_label>Neostigmine 25</arm_group_label>
    <arm_group_label>Neostigmine 5</arm_group_label>
    <arm_group_label>Neostigmine 50</arm_group_label>
    <other_name>Prostigmin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        people scheduled for elective surgery
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1 age of 18 to 65 yr,

          -  2 body mass index 18.5 to 25.0 kg/m2,

          -  3 American Society of Anesthesiologists physical status I to III

          -  4 male/female ratio 1:1

          -  5 scheduled for elective surgery with an expected duration of at least 60min under
             general anesthesia with intubation of the trachea or laryngeal mask

        Exclusion Criteria:

          -  1 patients who had participated in another clinical trial within 1 month

          -  2 Patients with suspected difficult airway, bronchial asthma, chronic obstructive
             pulmonary disease

          -  3 known neuromuscular disease

          -  4 suspected malignant hyperthermia

          -  5 hepatic or renal dysfunction

          -  6 glaucoma

          -  7 allergy to the medication that used in this trial

          -  8 taking medicaments that might influence the effect of NMB agents

          -  9 pregnant, or breastfeeding state

          -  10 taking medication known to alter the effect of neuromuscular blocking agents(
             toremifene .etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangzhou Military Region General Hospital, Department of Anesthesiology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Pongrácz A, Szatmári S, Nemes R, Fülesdi B, Tassonyi E. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. Anesthesiology. 2013 Jul;119(1):36-42. doi: 10.1097/ALN.0b013e318297ce95.</citation>
    <PMID>23665915</PMID>
  </reference>
  <reference>
    <citation>Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology. 2010 Nov;113(5):1054-60. doi: 10.1097/ALN.0b013e3181f4182a.</citation>
    <PMID>20885293</PMID>
  </reference>
  <reference>
    <citation>Kaufhold N, Schaller SJ, Stäuble CG, Baumüller E, Ulm K, Blobner M, Fink H. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,. Br J Anaesth. 2016 Feb;116(2):233-40. doi: 10.1093/bja/aev437.</citation>
    <PMID>26787792</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>bo xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>sugammadex neostigmine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

